Long-acting preparations of exenatide

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 963-970

  Cai, Yunpeng ^a,b   Wei, Liangming ^c   Ma, Liuqing ^b   Huang, Xiwen ^b   Tao, Anqi ^b   Liu, Zhenguo ^a   Yuan, Weien ^a,b  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c Shanghai Jiao Tong University   (China)

Author keywords

Diabetes mellitus type 2; Exendin 4; Extended release; Long acting; Microsphere; Sustained release

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BILE ACID; EXENDIN 4; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; HYALURONIC ACID; LIRAGLUTIDE; LONG ACTING DRUG; LYSINE; METFORMIN; MICROSPHERE; POLYGLACTIN; POLYSACCHARIDE;

BINDING AFFINITY; CHEWING GUM; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG IMPLANT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG RESPONSE; DRUG STABILITY; GASTROINTESTINAL DISEASE; GEL; GENE THERAPY; HUMAN; HYDROGEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; PHASE TRANSITION; REVIEW; SIDE EFFECT; SURFACE PROPERTY; SUSTAINED RELEASE PREPARATION; TABLET FORMULATION; WEIGHT REDUCTION;

DIABETES MELLITUS TYPE 2; EXENDIN-4; EXTENDED RELEASE; LONG ACTING; MICROSPHERE; SUSTAINED RELEASE;

ANIMALS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; VENOMS;

EID: 84884245248     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S46970     Document Type: Review

References (65)

1. Khafagy S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev. 2007;59(15):1521-1546.
2. Jin Y, Song YP, Zhu X, et al. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials. 2012;33(5):1573-1582.
3. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(9):1083-1091.
4. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002;51(1):7-18.
5. Pories WJ, Albrecht RJ. Etiology of type II diabetes mellitus: role of the foregut. World J Surg. 2001;25(4):527-531.
6. Cvetković RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs. 2007;67(6):935-954.
7. Triplitt C, Chiquette E. Exenatide: from the Gila monster to the pharmacy. J Am Pharm Assoc (2003). 2006;46(1):44-55.
8. Gentilella R, Bianchi C, Rossi A, Rotella CM. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab. 2009;11(6): 544-556.
9. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402-7405.
10. Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med. 2008;358(18):1969-1972.
11. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117(2):77-88.
12. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(7):3082-3089.
13. Painter NA, Morello CM, Singh RF, McBane SE. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes. J Am Board Fam Med. 2013;26(2):203-210.
14. Xiao L, Chen Q, Bao Y, Pan F. Release pattern improvement of nomegestrol from biodegradable microspheres by using polymer-alloys as matrix. Asian J Pharm Sci. 2010;5(6):231-238.
15. Jeyanthi R, Mehta RC, Thanoo BC, DeLuca PP. Effect of processing parameters on the properties of peptide-containing PLGA microspheres. J Microencapsul. 1997;14(2):163-174.
16. Nikou KN, Stivaktakis N, Avgoustakis K, et al. A HER-2/neu peptide admixed with PLA microspheres induces a Th1-biased immune response in mice. Biochim Biophys Acta. 2005;1725(2):182-189.
17. Wright SG, Christenson T, Yeah TY, et al, inventors; Alkermes Inc, assignee. Polymer-based sustained release device. United States patent US7456254 B2. November 1, 2008.
18. Li X, Li L, Wang X, Ren Y, Zhou T, Lu W. Application of model-based methods to characterize exenatide-loaded double-walled microspheres: in vivo release, pharmacokinetic/pharmacodynamic model, and in vitro and in vivo correlation. J Pharm Sci. 2012;101(10):3946-3961.
19. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11): 1145-1154.
20. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.
21. Norwood P, Liutkus JF, Haber H, et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther. 2012;34(10):2082-2090.
22. Wysham C, Grimm M, Chen S. Once weekly exenatide: efficacy, tolerability and place in therapy. Diabetes Obes Metab. Epub February 20, 2013.
23. Malone J, Trautmann M, Wilhelm K, et al. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2009;18(3):359-367.
24. Murphy CE. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2012;46(6):812-821.
25. Ridge T, Moretto T, Macconell L, et al. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(12):1097-1103.
26. Wang J, Wang BM, Schwendeman SP. Characterization of the initial burst release of a model peptide from poly (D, L-lactide-co-glycolide) microspheres. J Control Release, 2002;82(2):289-307.
27. Cleland JL. Solvent evaporation processes for the production of controlled release biodegradable microsphere formulations for therapeutics and vaccines. Biotechnol Progr. 1998;14(1):102-107.
28. Shi L, Liu B, Wang M, et al. Effect of molecular weight of poly(Lactic-co-Glycolide) on properties of exenatide-loaded microspheres. China Modern Medicine. 2009;7:117-118.
29. Kwak HH, Shim WS, Hwang S, et al. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats. Pharm Res. 2009;26(11):2504-2512.
30. Liu B, Dong Q, Wang M, et al. Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres. Chem Pharm Bull (Tokyo). 2010;58(11):1474-1479.
31. Kim H, Park H, Lee J, et al. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials. 2011;32(6):1685-1693.
32. Yang HJ, Park IS, Na K. Biocompatible microspheres based on acetylated polysaccharide prepared from water-in-oil-in-water (W1/O/W2) double-emulsion method for delivery of type II diabetic drug (exenatide). Colloids Surf A. 2009;340(1/3):115-120.
33. Hiemstra C, Zhou W, Zhong Z, Wouters M, Feijen J. Rapidly in situ forming biodegradable robust hydrogels by combining stereocomplexation and photopolymerization. J Am Chem Soc. 2007;129(32):9918-9926.
34. Vermonden T, Censi R, Hennink WE. Hydrogels for protein delivery. Chem Rev. 2012;112(5):2853-2888.
35. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol. 2008;20(2):86-100.
36. Li K, Yu L, Liu X, Chen C, Chen Q, Ding J. A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel. Biomaterials. 2013;34(11):2834-2842.
37. Joabsson FC, Johnsson MC, Tiberg FC, inventors; Camurus AB, Goddard C, applicants. GLP-1 analogue formulations. European patent EP1888031 A1. February 20, 2008.
38. Leitch JW, Gillis AM, Wyse DG, et al. Reduction in defibrillator shocks with an implantable device combining antitachycardia pacing and shock therapy. J Am Coll Cardiol. 1991;18(1):145-151.
39. Wilkins E, Atanasov P, Muggenburg BA. Integrated implantable device for long-term glucose monitoring. Biosensors and Bioelectronics. 1995;10(5):485-494.
40. Kuzma P, Decker S, Quandt H, inventors; Endo Pharmaceuticals Solutions Inc, assignee. Sustained delivery of exenatide and other peptides. United State patent US20100292144 A1. November 18, 2010.
41. Khandare J, Minko T. Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci. 2006;31(4):359-397.
42. Laman AG, Shepelyakovskaya AO, Boziev KM, et al. Structural modification effects on bioactivities of the novel 15-mer peptide adjuvant. Vaccine. 2011;29(44):7779-7784.
43. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 2002;283(4): E745-E752.
44. Pan CQ, Buxton JM, Yung SL, et al. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J Biol Chem. 2006;281(18):12506-12515.
45. Dhalluin C, Ross A, Leuthold LA, et al. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. Bioconjug Chem. 2005;16(3):504-517.
46. Kochendoerfer G. Chemical and biological properties of polymer-modified proteins. Expert Opin Biol Ther. 2003;3(8):1253-1261.
47. Park EJ, Tak TH, Na DH, Lee KC. Effect of PEGylation on stability of peptide in poly(lactide-co-glycolide) microspheres. Arch Pharm Res. 2010;33(7):1111-1116.
48. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451-1458.
49. Bendele A, Seely J, Richey C, Sennello G, Shopp G. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci. 1998;42(2):152-157.
50. Gong N, Ma AN, Zhang LJ, et al. Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. Brit J Pharmacol. 2011;163(2):399-412.
51. Hansen TK, Lau J, inventors; Novo Nordisk A/S, assignee. Protracted exendin-4 compounds. United States patent US20110301084 A1. December 8, 2011.
52. Schellenberger V, Wang CW, Geething NC, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009;27(12):1186-1190.
53. Kong JH, Oh EJ, Chae SY, Lee KC, Hahn SK. Long acting hyaluronate - Exendin 4 conjugate for the treatment of type 2 diabetes. Biomaterials. 2010;31(14):4121-4128.
54. Chae SY, Jin CH, Shin JH, et al. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release. 2010;142(2):206-213.
55. Chae SY, Choi YG, Son S, Jung SY, Lee DS, Lee KC. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J Control Release. 2010;144(1):10-16.
56. Lee J, Lee C, Kim I, et al. Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia. Int J Pharm. 2012;424(1/2):50-57.
57. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001;2(4):198-209.
58. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1(4):338-344.
59. Kim H, Lee J, Kim TH, et al. Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes. Pharm Res. 2011;28(8):2008-2019.
60. Andersen C, Lorenzen G, Arent N, Thorengaard B, Wittorff H, inventors and assignees. Compressed chewing gum tablet. United States patent US20100255063 A1. October 7, 2010.
61. Kim PH, Lee M, Kim SW. Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model. J Control Release. 2012; 162(1):9-18.
62. Léger R, Thibaudeau K, Robitaille M, et al. Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg Med Chem Lett. 2004;14(17):4395-4398.
63. Amiram M, Luginbuhl KM, Li X, Feinglos MN, Chilkoti A. Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control. Proc Natl Acad Sci U S A. 2013;110(8):2792-2797.
64. Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
65. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45(2):195-202.